GlassScriptPhysician profile
Laura A Perez
NPI 1700138625
$4,848.83
in general payments reported to CMS, 2019-2025
21 companies · $897 in 2025
The $897 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $816 · 2022: $769 · 2023: $1,035 · 2024: $1,332 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,029 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,028.99 |
| Education | $234.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $769.02 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $750.52 | 2021-2025 | |
| Genzyme Corporation | $435.48 | 2021-2025 | |
| Amgen INC. | $434.72 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $338.31 | 2021-2025 | Blu-U |
| Lilly USA, LLC | $320.15 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $261.54 | 2021-2025 | |
| Dermavant Sciences, INC. | $247.62 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $219.34 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $210.68 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $205.02 | 2024-2025 | Dupixent, Libtayo |
| Pfizer INC. | $172.05 | 2021-2023 | |
| Ucb, INC. | $102.38 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $101.22 | 2021-2025 | Epsolay, Oracea, Aklief |
| Incyte Corporation | $92.64 | 2022-2025 | Opzelura |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $60.63 | 2021-2022 | |
| Clozex Medical INC | $32.13 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.82 | 2024 | Spevigo |
| Allergan, INC. | $23.10 | 2021 | |
| Almirall LLC | $22.57 | 2021 | |
| Arcutis Biotherapeutics, INC. | $18.89 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.